Category: Oncology/Hematology
Global Oncology/Hematology
-
Global Pancreatic Cancer Market - 2024 - 2031
... to exhibit a CAGR of 11.1% during the forecast period (2024-2031). Chemotherapy medications are used to kill or stop cancer cell division. Adjuvant chemotherapy is administered after surgery to eradicate any cancer cells left over, ... Read More
-
Global Thymus Cancer Market - 2023-2030
... expected to exhibit a CAGR of 5.5% during the forecast period (2024-2031). The key players are adopting strategies such as partnerships, mergers, acquisitions, novel product launches and enhanced focus on R&D and regional expansion to ... Read More
-
Global Cancer Tumor Profiling Market - 2024 - 2031
... is a laboratory test to check for gene mutations or other alterations that make up the tumor biology and underlie the cancer growth. This information can help physicians build a personalized treatment plan based on ... Read More
-
Global Colorectal Cancer Drugs Market - 2024 - 2031
... Drugs Market is expected to exhibit a CAGR of 3.7% during the forecast period 2024-2031. The treatment of colorectal cancer typically involves a combination of surgery, radiation therapy, and chemotherapy. Besides, the treatment regimens for ... Read More
-
Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer ) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030
... by many rising impacts with respect to improving cases of respiratory diseases around the world. Innovative technologies in diagnosis, such as molecular diagnostics and advanced imaging solutions, have also improved the accuracy and speed of ... Read More
-
Global Immunotherapy Drugs Market (2025 Edition): Analysis By Indication (Cancer, Autoimmune & Inflammatory Diseases, Other Indications), By Drug Type, By Region, By Country: Market Insights and Forecast (2020-2030)
... & Inflammatory Diseases, Other Indications), By Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccines) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030. The report analyses the Immunotherapy Drugs Market ... Read More
-
Immunotherapy Drugs
... CAGR of 9.6% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$254.4 Billion by the end of the analysis ... Read More
-
Bulk Paclitaxel
... CAGR of 8.5% over the analysis period 2024-2030. Semi-Synthetic Paclitaxel API, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$139.1 Million by the end of the ... Read More
-
Breast Cancer Screening
... at a CAGR of 5.1% over the analysis period 2024-2030. Imaging Test, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$4.8 Billion by the end of ... Read More
-
Cancer Gene Therapy
... at a CAGR of 20.9% over the analysis period 2024-2030. Oncolytic Virotherapy, one of the segments analyzed in the report, is expected to record a 21.7% CAGR and reach US$4.3 Billion by the end of ... Read More
-
Multiple Myeloma Therapeutics
... at a CAGR of 14.5% over the analysis period 2024-2030. Chemotherapy & Other Drugs, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$37.6 Billion by the ... Read More
-
Prostate Cancer Therapeutics
... at a CAGR of 6.6% over the analysis period 2024-2030. Hormone Therapy, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$21.0 Billion by the end of ... Read More
-
Cancer Stem Cells
... at a CAGR of 8.5% over the analysis period 2024-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the ... Read More
-
Oncology Based In-Vivo CRO
... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Solid Tumors Indication, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$1.2 Billion by ... Read More
-
Cancer Supportive Care
... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
-
Oncology Information Systems
... at a CAGR of 6.2% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$5.5 Billion by the end of ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Breast Cancer Therapeutics
... at a CAGR of 12.3% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$74.9 Billion by the end of ... Read More
-
Brachytherapy
... 4.3% over the analysis period 2024-2030. High Dose Rate Brachytherapy, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$1.6 Billion by the end of the analysis ... Read More
-
Cancer Diagnostics
... CAGR of 5.8% over the analysis period 2024-2030. Imaging, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$95.3 Billion by the end of the analysis period. ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC) Therapeutics, one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by ... Read More
-
Prescription Drugs
... CAGR of 5.7% over the analysis period 2024-2030. Generic Drugsone of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$498.0 Billion by the end of the analysis period. ... Read More
-
Cancer Therapies
... CAGR of 10.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$112.8 Billion by the end of the analysis period. ... Read More
-
In-Vitro Colorectal Cancer Screening Tests
... Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach ... Read More
Research Assistance
